The United States Patent and Trademark Office (USPTO) has issued patent US12582648B2 to Bioprojet Pharma. This patent covers a method for treating or inhibiting central nervous system disorders such as restless leg syndrome, binge eating, essential tremor, and neurodegenerative diseases. The method specifically utilizes dopamine D3 partial agonists, including those with D2 antagonist properties.

This patent grant signifies a new intellectual property asset in the therapeutic area of CNS disorders. While not a regulatory rule imposing obligations on other entities, it represents a significant development for Bioprojet Pharma in its drug development efforts. Compliance officers in the pharmaceutical sector should be aware of this patent as it pertains to the therapeutic landscape for CNS treatments.